<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453750</url>
  </required_header>
  <id_info>
    <org_study_id>1000028032</org_study_id>
    <nct_id>NCT02453750</nct_id>
  </id_info>
  <brief_title>Airway Inflammation in Congenital Diaphragmatic Hernia Patients</brief_title>
  <official_title>Investigation of Airway Inflammation in Congenital Diaphragmatic Hernia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to examine Congenital Diaphragmatic Hernia (CDH) patients for evidence of airway
      inflammation as a first step to characterize the reported bronchodilator responsiveness.
      Airway biopsy studies are invasive and thus we propose to perform induced sputum studies to
      document the amount and type of inflammation present. Another ancillary non-invasive measure
      of airway inflammation that we will use is exhaled nitric oxide (NO). The primary objective
      of this study is to determine if CDH patients have any evidence of airway inflammation. The
      hypothesis of this study is that children with CDH do not have evidence of airway
      inflammation associated with bronchodilator responsiveness. Based on this information,
      treatment for CDH patients will hopefully be more accurate and appropriate for their specific
      needs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Elevated Sputum Eosinophils</measure>
    <time_frame>post sputum induction</time_frame>
    <description>Number of participants with sputum eosinophils greater than 3% percent of cells in the sputum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Elevated Sputum Neutrophils</measure>
    <time_frame>Baseline, +30 minutes</time_frame>
    <description>Elevation is defined as sputum neutrophils &gt; or = 61% neutrophils = neutrophilic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Elevated Exhaled Nitric Oxide (NO) Level</measure>
    <time_frame>30 min</time_frame>
    <description>exhaled NO measurements will be performed according to the American Thoracic Society and European Respiratory Society guidelines. These tests are performed routinely as part of the respiratory evaluation of these patients and are not additional tests added for this study.
greater than 20 ppb was considered elevated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Bronchodilator Response</measure>
    <time_frame>life time of child (age 6 to present age)</time_frame>
    <description>defined as a = or &gt; 12% change in FEV1 post bronchodilator</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Congenital Diaphragmatic Hernia</condition>
  <arm_group>
    <arm_group_label>Hypersaline and Bronchodilator Response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypersaline</intervention_name>
    <description>Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls &lt;10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls &gt;10%, the previous step will be repeated.</description>
    <arm_group_label>Hypersaline and Bronchodilator Response</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilator Response</intervention_name>
    <description>A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.</description>
    <arm_group_label>Hypersaline and Bronchodilator Response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 - 18 years of age at enrolment

          -  Clinically stable at enrolment

          -  Attending follow-up in the CDH Clinic at SickKids

        Exclusion Criteria:

          -  Unable to perform pulmonary function testing

          -  Clinically unstable at enrolment

          -  Known hypersensitivity to salbutamol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Moraes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>October 6, 2017</results_first_submitted>
  <results_first_submitted_qc>August 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2019</results_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Theo Moraes</investigator_full_name>
    <investigator_title>Staff Respirologist</investigator_title>
  </responsible_party>
  <keyword>Congenital Diaphragmatic Hernia</keyword>
  <keyword>Airway Inflammation</keyword>
  <keyword>Asthma</keyword>
  <keyword>Hypersaline</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernias, Diaphragmatic, Congenital</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Diaphragmatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypersaline and Bronchodilator Response</title>
          <description>Each child will perform a sputum induction to obtain cells for analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypersaline and Bronchodilator Response</title>
          <description>After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer to obtain cells for analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Elevated Sputum Eosinophils</title>
        <description>Number of participants with sputum eosinophils greater than 3% percent of cells in the sputum</description>
        <time_frame>post sputum induction</time_frame>
        <population>15 gave reasonable sputum for analysis, none had elevated sputum eosinophils</population>
        <group_list>
          <group group_id="O1">
            <title>Hypersaline and Bronchodilator Response</title>
            <description>everyone performs sputum induction</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elevated Sputum Eosinophils</title>
          <description>Number of participants with sputum eosinophils greater than 3% percent of cells in the sputum</description>
          <population>15 gave reasonable sputum for analysis, none had elevated sputum eosinophils</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Elevated Sputum Neutrophils</title>
        <description>Elevation is defined as sputum neutrophils &gt; or = 61% neutrophils = neutrophilic inflammation</description>
        <time_frame>Baseline, +30 minutes</time_frame>
        <population>15 gave reasonable sputum</population>
        <group_list>
          <group group_id="O1">
            <title>Hypersaline and Bronchodilator Response</title>
            <description>After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Elevated Sputum Neutrophils</title>
          <description>Elevation is defined as sputum neutrophils &gt; or = 61% neutrophils = neutrophilic inflammation</description>
          <population>15 gave reasonable sputum</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Elevated Exhaled Nitric Oxide (NO) Level</title>
        <description>exhaled NO measurements will be performed according to the American Thoracic Society and European Respiratory Society guidelines. These tests are performed routinely as part of the respiratory evaluation of these patients and are not additional tests added for this study.
greater than 20 ppb was considered elevated</description>
        <time_frame>30 min</time_frame>
        <population>only 12 performed eNO</population>
        <group_list>
          <group group_id="O1">
            <title>Hypersaline and Bronchodilator Response</title>
            <description>eNO measured</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Elevated Exhaled Nitric Oxide (NO) Level</title>
          <description>exhaled NO measurements will be performed according to the American Thoracic Society and European Respiratory Society guidelines. These tests are performed routinely as part of the respiratory evaluation of these patients and are not additional tests added for this study.
greater than 20 ppb was considered elevated</description>
          <population>only 12 performed eNO</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Bronchodilator Response</title>
        <description>defined as a = or &gt; 12% change in FEV1 post bronchodilator</description>
        <time_frame>life time of child (age 6 to present age)</time_frame>
        <population>all subjects performed PFTs</population>
        <group_list>
          <group group_id="O1">
            <title>Hypersaline and Bronchodilator Response</title>
            <description>spiro performed at start of visit</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Bronchodilator Response</title>
          <description>defined as a = or &gt; 12% change in FEV1 post bronchodilator</description>
          <population>all subjects performed PFTs</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypersaline and Bronchodilator Response</title>
          <description>After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Theo Moraes</name_or_title>
      <organization>SickKids</organization>
      <phone>416 813 2196</phone>
      <email>theo.moraes@sickkids.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

